Severe infections caused by Stenotrophomonas maltophilia are associated with high mortality, and strategies to improve the clinical outcome for infected patients are needed. A retrospective cohort study of patients with bloodstream infection (BSIs) and pneumonia caused by S. maltophilia was conducted. Multivariate analysis was performed to access factors associated with 14-day mortality. A total of 60 infections were identified. Among these, eight (13%) were pneumonias and 52 were BSIs; 33.3% were primary, 13% were central venous catheter (CVC)-related and 40% were secondary BSIs. Fifty-seven (85%) patients had received previous antimicrobial therapy; 88% had CVC, 57% mechanical ventilation and 75% were in the intensive care unit at the onset of infection. Malignancy (45%) was the most frequent underlying disease. The mean of the Acute Physiology and Chronic Health Evaluation II (APACHE II) scores was 17 and for the Sepsis-related Organ Failure Assessment (SOFA) score, it was 7 points. The overall and 14-day mortality were, respectively, 75% and 48%. Forty-seven (78%) patients were treated and, of these, 74% received trimethoprim-sulfamethoxazole. Independent risk factors associated with mortality were SOFA index >6 points (0.005) and septic shock (0.03). The Kaplan-Meier estimations curves showed that patients with APACHE II score >20 and SOFA score >10 had a survival chance of, respectively, less than 8% and less than 10% (P≤0.001) at 21 days after the first positive S. maltophilia culture. Our results suggest that the independent factors associated with outcome in patients with infection caused by S. maltophilia are septic shock and higher SOFA index.
Septic Shock Central Venous Catheter Intensive Care Unit Patient Multiple Organ Dysfunction Syndrome Acinetobacter Baumannii
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
We thank Dr. Lorena Laborda and Dr. Maura S. Oliveira for their support in this study.
This study was approved by the ethics committee of the Hospital das Clínicas of the University of São Paulo Medical School, São Paulo, Brazil.
Potential conflicts of interest statement
All authors: no conflicts.
All authors: no financial support.
Lai CH, Chi CY, Chen HP et al (2004) Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 37:350–358PubMedGoogle Scholar
Hanes SD, Demirkan K, Tolley E et al (2002) Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 35:228–235PubMedCrossRefGoogle Scholar
Muder RR, Harris AP, Muller S et al (1996) Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 22:508–512PubMedGoogle Scholar
Micozzi A, Venditti M, Monaco M et al (2000) Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 31:705–711PubMedCrossRefGoogle Scholar
Victor MA, Arpi M, Bruun B et al (1994) Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis 26:163–170PubMedCrossRefGoogle Scholar
Friedman ND, Korman TM, Fairley CK et al (2002) Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 45:47–53PubMedCrossRefGoogle Scholar
Elting LS, Khardori N, Bodey GP et al (1990) Nosocomial infection caused by Xanthomonas maltophilia: a case–control study of predisposing factors. Infect Control Hosp Epidemiol 11:134–138PubMedCrossRefGoogle Scholar
del Toro MD, Rodríguez-Baño J, Herrero M et al (2002) Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine (Baltimore) 81:228–239CrossRefGoogle Scholar
Carmeli Y, Samore MH (1997) Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis 24:1131–1134PubMedCrossRefGoogle Scholar
Denton M, Kerr KG (1998) Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 11:57–80PubMedGoogle Scholar
Senol E, DesJardin J, Stark PC et al (2002) Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 34:1653–1656PubMedCrossRefGoogle Scholar
Wang WS, Liu CP, Lee CM et al (2004) Stenotrophomonas maltophilia bacteremia in adults: four years’ experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 37:359–365PubMedGoogle Scholar
del Toro MD, Rodríguez-Baño J, Martínez-Martínez L et al (2006) Características epidemiológicas, clínicas y pronósticas de la infección por Stenotrophomonas maltophilia. Enferm Infecc Microbiol Clin 24:4–9PubMedCrossRefGoogle Scholar
Tsiodras S, Pittet D, Carmeli Y et al (2000) Clinical implications of Stenotrophomonas malthophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 32:651–656PubMedCrossRefGoogle Scholar
McCabe WR, Jackson GG (1962) Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 110:847–855Google Scholar
Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710PubMedCrossRefGoogle Scholar
Knaus WA, Draper EA, Wagner DP et al (1985) APACHE II: a severity of disease classification system. Crit Car Med 13:818–829CrossRefGoogle Scholar
Garner JS, Jarvis WR, Emori TG et al (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128–140PubMedCrossRefGoogle Scholar
[No authors listed] (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874Google Scholar
Clinical and Laboratory Standards Institute (CLSI) (2005) Performance standards for antimicrobial susceptibility testing. Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PAGoogle Scholar
Aisenberg G, Rolston KV, Dickey BF et al (2007) Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997–2004. Eur J Clin Microbiol Infect Dis 26:13–20PubMedCrossRefGoogle Scholar
Metan U, Uzun O (2005) Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother 49:3980–3981PubMedCrossRefGoogle Scholar
Morrison AJ Jr, Hoffmann KK, Wenzel RP (1986) Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 24:52–55PubMedGoogle Scholar
Nicodemo AC, Garcia Paez JI (2007) Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 26:229–237PubMedCrossRefGoogle Scholar
Boktour M, Hanna H, Ansari S et al (2006) Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer 106:1967–1973PubMedCrossRefGoogle Scholar